Transcriptome in Huntington's disease and Huntington's disease-like 2

亨廷顿病和类亨廷顿病 2 的转录组

• 批准号: 8390995
• 负责人: RUSSELL L MARGOLIS
• 金额: $ 28.18万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-06-01 至 2013-01-01
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8390995
• 关键词: 16q; Adult; Affect; American; Autopsy; Bioinformatics; Biological Assay; Biological Models; Brain; Brain region; Brodmann' s area; Chromosomes; Data; Defect; Disease; Exons; Functional disorder; Gene Expression; Gene Expression Profile; Generations; Genes; Human; Huntington Disease; Label; Lead; Length; Methods; Molecular; Molecular Target; Motor Cortex; Mus; Neurodegenerative Disorders; Pathogenesis; Pathway interactions; Patients; Pattern; Proteomics; Protocols documentation; RNA; RNA Processing; RNA Sequence Analysis; RNA Sequences; RNA Splicing; RNA Transport; Relative (related person); Resolution; Resources; Reverse Transcriptase Polymerase Chain Reaction; Risk; Role; Sampling; Spliced Genes; System; Technology; Testing; Toxic effect; Transcript; Transgenes; Transgenic Organisms; Triplet Multiple Birth; Validation; base; brain tissue; density; effective therapy; frontal lobe; genome-wide; genome-wide analysis; human Huntingtin protein; human data; improved; insight; junctophilin; mind control; mouse model; mutant; novel; novel strategies; polyglutamine; therapeutic development; therapeutic target; tool

DESCRIPTION (provided by applicant): Huntington's disease (HD) and Huntington's disease-like 2 (HDL2) are remarkably similar autosomal dominant adult onset neurodegenerative disorders, nearly indistinguishable clinically and pathologically. Each disease is ultimately fatal with no effective treatment to stop or slow the relentless progression. HD affects about 30,000 Americans, with a much higher number at risk; HDL2 is rare. The complete explanation for HD and HDL2 pathogenesis remains elusive. A novel strategy for focusing the search for disease mechanisms and therapeutic targets of HD is to determine those points at which the pathogenic pathways of HD and HDL2 converge. A particularly powerful method for implementing this strategy is to compare the transcriptomes of the two diseases. Based on our preliminary evidence, we hypothesize that both abnormal levels of gene expression and abnormal gene splicing will be present in HD and HDL2 and that the sets of these abnormalities will overlap in the two diseases. Here we propose to take advantage of the remarkable similarities of HD and HDL2 to identify convergent pathogenic pathways, via parallel transcriptome characterization of mouse models and human patient samples of HD and HDL2. We propose two specific aims. In aim 1, we will use state of the art exon junction array, RNA sequencing (RNA-Seq), and analytic methods to examine and compare RNA extracted from human HD and HDL2 postmortem brains and mouse models of HD and HDL2 as well as controls. In aim 2, we will experimentally validate expression and splicing abnormalities using high-throughput automated PCR assays and new RNA samples, compare mouse and human data, and use bioinformatics tools to determine common gene sets, pathways, and molecular subnetworks shared by genes showing gene expression or splicing abnormalities in HD and HDL2 brains. We anticipate that the proposed studies will create an extremely valuable resource that will provide a detailed characterization of the HD and HDL2 transcriptomes at an unprecedented resolution and hence fundamentally improve understanding of disease pathophysiology. PUBLIC HEALTH RELEVANCE: Huntington's disease (HD) and Huntington's disease-like 2 (HDL2) are remarkably similar autosomal dominant adult onset neurodegenerative disorders, nearly indistinguishable clinically and pathologically. This project will conduct a comprehensive examination and comparison of HD and HDL2 transcriptomes to identify defects in gene expression and splicing in diseased brains. These studies will lead to a better understanding of HD and HDL2 pathophysiology, and may reveal novel molecular targets and pathways for therapeutic development.

描述（由申请人提供）：亨廷顿病（HD）和亨廷顿病样2（HDL 2）是非常相似的常染色体显性成人发病神经退行性疾病，在临床和病理上几乎无法区分。每种疾病最终都是致命的，没有有效的治疗方法来阻止或减缓这种无情的进展。HD影响约30，000名美国人，风险人数要高得多; HDL 2很罕见。HD和HDL 2发病机制的完整解释仍然难以捉摸。一种新的策略，专注于HD的疾病机制和治疗靶点的搜索是确定这些点的HD和HDL 2的致病途径收敛。实施这一策略的一个特别有效的方法是比较这两种疾病的转录组。基于我们的初步证据，我们假设HD和HDL 2中存在基因表达水平异常和基因剪接异常，并且这两种疾病中这些异常的集合将重叠。在这里，我们建议利用HD和HDL 2的显著相似性，通过HD和HDL 2的小鼠模型和人类患者样本的平行转录组表征来识别会聚的致病途径。我们提出两个具体目标。在目标1中，我们将使用最先进的外显子连接阵列、RNA测序（RNA-Seq）和分析方法来检查和比较从人HD和HDL 2死后大脑和HD和HDL 2小鼠模型以及对照中提取的RNA。在目标2中，我们将使用高通量自动PCR检测和新的RNA样本，比较小鼠和人类数据，并使用生物信息学工具来确定HD和HDL 2大脑中显示基因表达或剪接异常的基因所共有的共同基因集、途径和分子子网络。我们预计，拟议的研究将创造一个非常有价值的资源，将提供一个详细的表征HD和HDL 2转录组在一个前所未有的分辨率，从而从根本上提高疾病的病理生理学的理解。 公共卫生相关性：亨廷顿病（HD）和亨廷顿病样2（HDL 2）是非常相似的常染色体显性成人发病的神经退行性疾病，在临床和病理上几乎难以区分。该项目将对HD和HDL 2转录组进行全面的检查和比较，以确定患病大脑中基因表达和剪接的缺陷。这些研究将有助于更好地了解HD和HDL 2的病理生理学，并可能揭示新的分子靶点和治疗开发途径。